IMGO: Imago BioSciences, Inc. - Summary | Jitta

Imago BioSciences, Inc.

NASDAQ:IMGO

Notice
Stock data is unavailable or the company’s delisted.
Price
$36.01
Loss Chance
58.4%
0.63JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (6)
Financial Strength (32)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
SG&A to SalesDecreasing Every Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 41.31% in the last quarter (yoy)
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.63
100.00%
2.22
142.14%
3.06
209.62%
Biotechnology
6.05
120.49%
6.24
37.96%
4.69
49.83%
COMPANY DESCRIPTION
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California. As of January 11, 2023, Imago BioSciences, Inc. operates as a subsidiary of Merck Sharp & Dohme Corp..